More than half million women worldwide are diagnosed with cervical carcinoma every year and more than 273,000 die from the disease. According to the World Health Organization, this disease is the second most common cause of cancer death in women (9% of female cancer deaths every year). More than 99% of cervical carcinoma cases worldwide are caused by the human papilloma viruses (HPV).
Kit HPV High Risk Screen Real TM Quant is an in vitro Real-Time amplification tests for quantitative detection of Human Papillomavirus (16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) in the urogenital swabs. It being known, that the parameter of viral load has a prognostic value and the viral load less than 105 HPV genomic equivalents in the swab or 103 genomic equivalents for 105 cells is considered as insignificant and indicates the presence of transitory infection, however such level of load may have a value only in cases of treatment monitoring. Viral load of more than 105 genomic equivalents for 105 cells is considered to be important with high significance and indicates the existence of dysplastic changes or high risk of their occurrence. Quantitative detection of viral load allows to evaluate the character of the infection and to make a forecast concerning the stage of the disease.
HPV High Risk Screen Real TM Quant detect the most widespread and oncogenic 12 genotypes of human papilloma virus with determination of clinical significance. Since the human papilloma virus is an intracellular agent, there is need to monitor the presence of cellular material in the sample, in order to avoid false-negative results. HPV High Risk Screen Real TM Quant kit contains the internal control (human beta-globine gene) , which allows to control the presence of cellular material in the sample. Additionally, contact us for information regarding HPV High Risk Qualitative and Genotyping Detection kits.